A Phase I Study of Weekly Everolimus (RAD001) in Combination with Docetaxel in Patients with Metastatic Breast Cancer

BACKGROUND: Inhibition of mTOR with everolimus may result improve efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK) interaction. PATIENTS AND METHODS: 15 patients with metastatic breast cancer were treated with docetaxel (doses...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Moulder, Stacy, Gladish, Gregory, Ensor, Joe, Gonzalez-Angulo, Ana Maria, Cristofanilli, Massimo, Murray, James L., Booser, Daniel, Giordano, Sharon H., Brewster, Abeena, Moore, Julia, Rivera, Edgardo, Hortobagyi, Gabriel N., Tran, Hai T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3893000/
https://ncbi.nlm.nih.gov/pubmed/22006179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26571
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια